Vaxart Revenue, Growth & Competitor Profile

DBA Aviragen Therapeutics, Inc.
DBA Biota Pharmaceuticals, Inc.
DBA NABI BIOPHARMACEUTICALS

Company Profile & Annual Report for Vaxart

Access the complete profile.

Vaxart Fast Facts

Revenue	$100 - $500 million    See Exact Annual Revenue
Employees	100 - 500Exact Company Size
Primary Industry	325411 Medicinal & Botanical Manufacturing
Additional NAICS Codes	5417 Scientific Research & Development Services 541711 Research & Development in Biotechnology
Address	170 Harbor Way Suite 300 South San Francisco, CA 94080

Note: Revenues for privately held companies are statistical evaluations.


Vaxart's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Vaxart's annual revenues are $100 - $500 million (see exact revenue data)
• What industry is the company in?
  • Vaxart is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.

Vaxart Annual Revenue and Growth Rate

Vaxart	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2023	$100 - $500 million Details in Premium Report
2022
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Vaxart's revenues are gauged from an analysis of company filings.

Vaxart's Income Statement (based on Industry Averages)

Vaxart P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Vaxart is developing and marketing. Vaxart doesn't have any recent trademark applications, indicating Vaxart is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
VAAST ORAL VACCINES FOR USE IN HUMANS	10/01/2018
AVIRAGEN THERAPEUTICS pharmaceutical and chemical research and development	04/25/2016
BIOTA Vaccines, pharmaceutical preparations, drugs and diagnostic preparations for clinical and medical use as anti-infectives, namely, antivirals and antibacterials for use in the treatment or diagnosis of infectious diseases and conditions	03/16/2012

See all trademarks and details in the Full Report.

Market Share of Vaxart's Largest Competitors

A competitive analysis shows these companies are in the same general field as Vaxart, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
XYMOGEN	Orlando, FL	100
AVANTI NUTRITIONAL LABORATORIES	Miami Lakes, FL	37
NUTRITION FORMULATORS	Miramar, FL	36
RTPR	Cabot, AR	33
INTEGRATED BOTANICS	Fort Worth, TX	29
COSMAX NBT USA	Garland, TX	29
CJB INDUSTRIES	Valdosta, GA	28
ALTERNATIVE LABORATORIES	Naples, FL	28
S&B PHARMA	Azusa, CA	28

Nearby Competitors

These companies are similar in business line and location to Vaxart. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
GENENTECH	South San Francisco, CA	100
IGM BIOSCIENCES	Mountain View, CA	1
AKASA	South San Francisco, CA	1
MYOKARDIA	South San Francisco, CA	1
KRIYA THERAPEUTICS	Redwood City, CA	1
EPICRISPR BIOTECHNOLOGIES	South San Francisco, CA	1

Future Competition: Vaxart's Fastest Growing Competitors

These companies are in the same general field as Vaxart and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)